177 related articles for article (PubMed ID: 33622165)
21. Comment on: A newborn with a large NTRK fusion positive infantile fibrosarcoma successfully treated with larotrectinib.
Slomovic A; Amaral T; Lobko I; Siegel DN; Goldfisher R; Kessel R; Levy CF
Pediatr Blood Cancer; 2021 Jun; 68(6):e28953. PubMed ID: 33694317
[No Abstract] [Full Text] [Related]
22. Clinicopathological findings of pediatric NTRK fusion mesenchymal tumors.
Kang J; Park JW; Won JK; Bae JM; Koh J; Yim J; Yun H; Kim SK; Choi JY; Kang HJ; Kim WS; Shin JH; Park SH
Diagn Pathol; 2020 Sep; 15(1):114. PubMed ID: 32957984
[TBL] [Abstract][Full Text] [Related]
23. Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib.
Kummar S; Berlin J; Mascarenhas L; van Tilburg CM; Geoerger B; Lassen UN; Schilder RJ; Turpin B; Nanda S; Keating K; Childs BH; Chirila C; Laetsch TW; Hyman DM; Drilon A; Hong DS
Curr Probl Cancer; 2021 Dec; 45(6):100734. PubMed ID: 33865615
[TBL] [Abstract][Full Text] [Related]
24. TRK Inhibitors: Clinical Development of Larotrectinib.
Bhangoo MS; Sigal D
Curr Oncol Rep; 2019 Feb; 21(2):14. PubMed ID: 30715603
[TBL] [Abstract][Full Text] [Related]
25. Larotrectinib followed by selitrectinib in a novel
Goh XN; Seng MS; Loh AHP; Gupta A; Chang KTE; Iyer P
J Oncol Pharm Pract; 2021 Mar; 27(2):485-489. PubMed ID: 32693686
[TBL] [Abstract][Full Text] [Related]
26. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.
Hong DS; DuBois SG; Kummar S; Farago AF; Albert CM; Rohrberg KS; van Tilburg CM; Nagasubramanian R; Berlin JD; Federman N; Mascarenhas L; Geoerger B; Dowlati A; Pappo AS; Bielack S; Doz F; McDermott R; Patel JD; Schilder RJ; Tahara M; Pfister SM; Witt O; Ladanyi M; Rudzinski ER; Nanda S; Childs BH; Laetsch TW; Hyman DM; Drilon A
Lancet Oncol; 2020 Apr; 21(4):531-540. PubMed ID: 32105622
[TBL] [Abstract][Full Text] [Related]
27. Mixed response and mechanisms of resistance to larotrectinib in metastatic carcinoma ex pleomorphic adenoma of the parotid harboring an NTRK2 fusion: A case report.
Pircher M; Briner HR; Bonomo M; Horcic M; Petrausch U; Helbling D; Winder T
Medicine (Baltimore); 2021 Jan; 100(4):e24463. PubMed ID: 33530256
[TBL] [Abstract][Full Text] [Related]
28. Recurrent BRAF Gene Fusions in a Subset of Pediatric Spindle Cell Sarcomas: Expanding the Genetic Spectrum of Tumors With Overlapping Features With Infantile Fibrosarcoma.
Kao YC; Fletcher CDM; Alaggio R; Wexler L; Zhang L; Sung YS; Orhan D; Chang WC; Swanson D; Dickson BC; Antonescu CR
Am J Surg Pathol; 2018 Jan; 42(1):28-38. PubMed ID: 28877062
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors.
Doz F; van Tilburg CM; Geoerger B; Højgaard M; Øra I; Boni V; Capra M; Chisholm J; Chung HC; DuBois SG; Gallego-Melcon S; Gerber NU; Goto H; Grilley-Olson JE; Hansford JR; Hong DS; Italiano A; Kang HJ; Nysom K; Thorwarth A; Stefanowicz J; Tahara M; Ziegler DS; Gavrilovic IT; Norenberg R; Dima L; De La Cuesta E; Laetsch TW; Drilon A; Perreault S
Neuro Oncol; 2022 Jun; 24(6):997-1007. PubMed ID: 34850167
[TBL] [Abstract][Full Text] [Related]
30. Larotrectinib as an Effective Therapy in Congenital Infantile Fibrosarcoma: Report of Two Cases.
Lapeña LM; Caldas MCS; Ramírez C; Basilio MS; Junco PT; Rodríguez-Laguna L; Martínez-González V; Marín-Manzano E; Perez-Martinez A; Lopez-Gutierrez JC
European J Pediatr Surg Rep; 2022 Jan; 10(1):e76-e79. PubMed ID: 35761904
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Drilon A; Laetsch TW; Kummar S; DuBois SG; Lassen UN; Demetri GD; Nathenson M; Doebele RC; Farago AF; Pappo AS; Turpin B; Dowlati A; Brose MS; Mascarenhas L; Federman N; Berlin J; El-Deiry WS; Baik C; Deeken J; Boni V; Nagasubramanian R; Taylor M; Rudzinski ER; Meric-Bernstam F; Sohal DPS; Ma PC; Raez LE; Hechtman JF; Benayed R; Ladanyi M; Tuch BB; Ebata K; Cruickshank S; Ku NC; Cox MC; Hawkins DS; Hong DS; Hyman DM
N Engl J Med; 2018 Feb; 378(8):731-739. PubMed ID: 29466156
[TBL] [Abstract][Full Text] [Related]
32. An infant with ETV6-NTRK3 fusion-positive congenital infantile fibrosarcoma and delayed response to conventional chemotherapy avoiding the need for TRK inhibition.
Vedi A; Holland K; Cross J; Muthusamy B; Behjati S; Hook CE; Murray MJ
Pediatr Blood Cancer; 2020 Oct; 67(10):e28628. PubMed ID: 32748441
[No Abstract] [Full Text] [Related]
33. Infantile fibrosarcoma-like tumor driven by novel
Gupta A; Belsky JA; Schieffer KM; Leraas K; Varga E; McGrath SD; Koo SC; Magrini V; Wilson RK; White P; Mardis ER; Jatana KR; Cottrell CE; Setty BA
Cold Spring Harb Mol Case Stud; 2020 Oct; 6(5):. PubMed ID: 33028644
[TBL] [Abstract][Full Text] [Related]
34. Testing algorithm for identification of patients with TRK fusion cancer.
Penault-Llorca F; Rudzinski ER; Sepulveda AR
J Clin Pathol; 2019 Jul; 72(7):460-467. PubMed ID: 31072837
[TBL] [Abstract][Full Text] [Related]
35. Discovery of a rare
Deland L; Keane S; Olsson Bontell T; Sjögren H; Fagman H; Øra I; De La Cuesta E; Tisell M; Nilsson JA; Ejeskär K; Sabel M; Abel F
Cancer Biol Ther; 2021 Mar; 22(3):184-195. PubMed ID: 33820494
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion-Positive Lung Cancers.
Drilon A; Tan DSW; Lassen UN; Leyvraz S; Liu Y; Patel JD; Rosen L; Solomon B; Norenberg R; Dima L; Brega N; Shen L; Moreno V; Kummar S; Lin JJ
JCO Precis Oncol; 2022 Jan; 6():e2100418. PubMed ID: 35085007
[TBL] [Abstract][Full Text] [Related]
37. Survival Outcomes of Patients With Tropomyosin Receptor Kinase Fusion-Positive Cancer Receiving Larotrectinib Versus Standard of Care: A Matching-Adjusted Indirect Comparison Using Real-World Data.
Bokemeyer C; Paracha N; Lassen U; Italiano A; Sullivan SD; Marian M; Brega N; Garcia-Foncillas J
JCO Precis Oncol; 2023 Jan; 7():e2200436. PubMed ID: 36689698
[TBL] [Abstract][Full Text] [Related]
38. Molecular detection of the ETV6-NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors.
Bourgeois JM; Knezevich SR; Mathers JA; Sorensen PH
Am J Surg Pathol; 2000 Jul; 24(7):937-46. PubMed ID: 10895816
[TBL] [Abstract][Full Text] [Related]
39. [A Case of Pediatric Soft Tissue Sarcoma with LMNA-NTRK1 Gene Fusion Treated with Larotrectinib under Single Patient Expanded Access System].
Kato S; Fujimura J; Nozaki Y; Yamaguchi S; Takagi T; Hayashi T; Saito T; Henry D; Ku N; Suehara Y
Gan To Kagaku Ryoho; 2019 Oct; 46(10):1595-1597. PubMed ID: 31631147
[TBL] [Abstract][Full Text] [Related]
40. Rapid Response to Larotrectinib (LOXO-101) in an Adult Chemotherapy-Naive Patients With Advanced Triple-Negative Secretory Breast Cancer Expressing ETV6-NTRK3 Fusion.
Landman Y; Ilouze M; Wein S; Neiman V; Yerushalmi R; Yakimov M; Ku N; Schrock AB; Ali S; Peled N
Clin Breast Cancer; 2018 Jun; 18(3):e267-e270. PubMed ID: 29233640
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]